CN108602829A - Cxcr4受体拮抗剂 - Google Patents

Cxcr4受体拮抗剂 Download PDF

Info

Publication number
CN108602829A
CN108602829A CN201680081803.1A CN201680081803A CN108602829A CN 108602829 A CN108602829 A CN 108602829A CN 201680081803 A CN201680081803 A CN 201680081803A CN 108602829 A CN108602829 A CN 108602829A
Authority
CN
China
Prior art keywords
methyl
alkyl
base
bases
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680081803.1A
Other languages
English (en)
Chinese (zh)
Inventor
G.M.施勒德
T.N.黄
H.L.佩雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108602829A publication Critical patent/CN108602829A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680081803.1A 2015-12-15 2016-12-14 Cxcr4受体拮抗剂 Pending CN108602829A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267649P 2015-12-15 2015-12-15
US62/267649 2015-12-15
PCT/US2016/066575 WO2017106291A1 (en) 2015-12-15 2016-12-14 Cxcr4 receptor antagonists

Publications (1)

Publication Number Publication Date
CN108602829A true CN108602829A (zh) 2018-09-28

Family

ID=57755467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680081803.1A Pending CN108602829A (zh) 2015-12-15 2016-12-14 Cxcr4受体拮抗剂

Country Status (6)

Country Link
US (1) US10450318B2 (enExample)
EP (1) EP3390406A1 (enExample)
JP (1) JP6856648B2 (enExample)
KR (1) KR102738306B1 (enExample)
CN (1) CN108602829A (enExample)
WO (1) WO2017106291A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403510A (zh) * 2022-08-11 2022-11-29 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156595A1 (en) 2017-02-21 2018-08-30 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
EP1799671A4 (en) 2004-09-02 2009-06-10 Smithkline Beecham Corp CHEMICAL COMPOUNDS
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006076131A2 (en) 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
ME02461B (me) 2005-05-10 2017-02-20 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
HUE025209T2 (en) 2005-07-22 2016-03-29 Lilly Co Eli Pyridine quinoline substituted pyrrolo [1,2-b] pyrazole monohydrate as TGF-beta inhibitor
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US20100280010A1 (en) * 2006-01-25 2010-11-04 Kristjan Gudmundsson Chemical compounds
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
PT2234620E (pt) 2008-01-03 2016-06-20 Université D`Aix-Marseille Terapia tripla usada para o tratamento dum paciente infetado por hiv
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN107011438B (zh) 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
NO2694640T3 (enExample) 2011-04-15 2018-03-17
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2012374617B2 (en) 2012-05-11 2015-09-17 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115403510A (zh) * 2022-08-11 2022-11-29 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Also Published As

Publication number Publication date
KR102738306B1 (ko) 2024-12-03
EP3390406A1 (en) 2018-10-24
US10450318B2 (en) 2019-10-22
JP6856648B2 (ja) 2021-04-07
JP2019502680A (ja) 2019-01-31
KR20180094036A (ko) 2018-08-22
US20180327409A1 (en) 2018-11-15
WO2017106291A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
JP6482629B2 (ja) Ｔｒｋａキナーゼ阻害剤としてのｎ−ピロリジニル、ｎ’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
CN102281875B (zh) 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
CN101686989B (zh) 取代的咪唑并杂环
CN103038233B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN112165944B (zh) 转录激活蛋白的咪唑并哌嗪抑制剂
CN115873020A (zh) Ras抑制剂
CN115605463B (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
CN114728962A (zh) 血浆激肽释放酶抑制剂及其用途
US9708316B2 (en) TGFβR antagonists
CN102014914A (zh) 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
KR20240026526A (ko) Ras를 억제하는 방법
EA038071B1 (ru) СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53
TW200908983A (en) Heterocyclic compounds and uses thereof
CN104470924A (zh) 作为tnf活性调节剂的咪唑并吡嗪衍生物
CN102803265A (zh) 吡咯并吡嗪激酶抑制剂
CN110582495A (zh) 作为tnf活性的调节剂的稠合五环咪唑衍生物
JP2014528482A (ja) Ｉｉｉ型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
CN108602829A (zh) Cxcr4受体拮抗剂
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
US20190292179A1 (en) TGF Beta RECEPTOR ANTAGONISTS
WO2022117882A2 (en) Novel par-2 inhibitors
JP2018526344A (ja) Ｔｇｆベータ受容体アンタゴニスト
CN120513245A (zh) 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180928

WD01 Invention patent application deemed withdrawn after publication